VTechWorks staff will be away for the winter holidays starting Tuesday, December 24, 2024, through Wednesday, January 1, 2025, and will not be replying to requests during this time. Thank you for your patience, and happy holidays!
 

Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: A focus on hapten localization

Simple item page
dc.contributor.authorZhao, Zongminen
dc.contributor.authorHu, Yunen
dc.contributor.authorHarmon, Theresaen
dc.contributor.authorPentel, Paulen
dc.contributor.authorEhrich, Marion F.en
dc.contributor.authorZhang, Chenmingen
dc.contributor.departmentBiological Systems Engineeringen
dc.contributor.departmentBiomedical Sciences and Pathobiologyen
dc.date.accessioned2018-01-03T15:47:40Zen
dc.date.available2018-01-03T15:47:40Zen
dc.date.issued2017-09-01en
dc.description.abstractA lipid-polymeric hybrid nanoparticle-based next-generation nicotine nanovaccine was rationalized in this study to combat nicotine addiction. A series of nanovaccines, which had nicotine-haptens localized on carrier protein (LPKN), nanoparticle surface (LPNK), or both (LPNKN), were designed to study the impact of hapten localization on their immunological efficacy. All three nanovaccines were efficiently taken up and processed by dendritic cells. LPNKN induced a significantly higher immunogenicity against nicotine and a significantly lower anti-carrier protein antibody level compared to LPKN and LPNK. Meanwhile, it was found that the anti-nicotine antibodies elicited by LPKN and LPNKN bind nicotine stronger than those elicited by LPKN, and LPNK and LPNKN resulted in a more balanced Th1-Th2 immunity than LPKN. Moreover, LPNKN exhibited the best ability to block nicotine from entering the brain of mice. Collectively, the results demonstrated that the immunological efficacy of the hybrid nanoparticle-based nicotine vaccine could be enhanced by modulating hapten localization, providing a promising strategy to combatting nicotine addiction.en
dc.description.notesfalse (Extension publication?)en
dc.description.versionPublished versionen
dc.format.extent46 - 56 page(s)en
dc.format.mimetypeapplication/pdfen
dc.identifier.orcidZhang, C [0000-0002-6770-5334]en
dc.identifier.urihttp://hdl.handle.net/10919/81487en
dc.identifier.volume138en
dc.language.isoenen
dc.rightsIn Copyrighten
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/en
dc.titleRationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: A focus on hapten localizationen
dc.title.serialBiomaterialsen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/Agriculture & Life Sciencesen
pubs.organisational-group/Virginia Tech/Agriculture & Life Sciences/Biological Systems Engineeringen
pubs.organisational-group/Virginia Tech/Agriculture & Life Sciences/CALS T&R Facultyen
pubs.organisational-group/Virginia Tech/All T&R Facultyen
pubs.organisational-group/Virginia Tech/University Research Institutesen
pubs.organisational-group/Virginia Tech/University Research Institutes/Fralin Life Sciencesen
pubs.organisational-group/Virginia Tech/University Research Institutes/Fralin Life Sciences/Fralin Affiliated Facultyen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2017-Biomaterials-Zongmin2.pdf
Size:
4.62 MB
Format:
Adobe Portable Document Format
Description:
Publisher's Version
Download
License bundle
Now showing 1 - 1 of 1
Name:
VTUL_Distribution_License_2016_05_09.pdf
Size:
18.09 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

All Faculty Deposits
Scholarly Works, Biological Systems Engineering
Scholarly Works, Biomedical Sciences and Pathobiology